JLL Partners related stories
All articles and analysis
- PE-backed MedPlast completes buy of Vention Medical device manufacturing services unit
MedPlast Inc, which is backed by JLL Partners and Water Street Healthcare Partners, has closed its previously announced acquisition of Vention Medical‘s device manufacturing services business. No financial terms were disclosed.
- PE-backed MedPlast to buy Vention Medical's device manufacturing services unit
MedPlast Inc, which is backed by JLL Partners and Water Street Healthcare Partners, has agreed to acquire Vention Medical's device manufacturing services business. No financial terms were disclosed. The deal is expected to close in the second quarter of this year.
- Chan joins 1315 Capital as a principal
Philadelphia-based growth equity firm 1315 Capital LLC has named Edward Chan as a principal. Previously, Chan worked at NaviMed Capital where he most recently served as a vice president. And prior to that, Chan was at Siemens Venture Capital where he evaluated and sourced healthcare deals.
- Water Street and JLL Partners buys MedPlast
Water Street Healthcare Partners and JLL Partners have acquired Tempe, Arizona-based MedPlast Inc, a medical device services provider. No financial terms were disclosed.
- Highview beefs up team with six new additions
Highview Capital LLC has expanded its team with six new hires. Joining the Los Angeles-based firm, which is backed by Karlin Asset Management, are Brice Baradel and Steve Russell as principals; P.J. Gilbert and Dan Picmann as vice presidents; and Tim Park and Kapish Haldia as associates.
- Cinven acquires $1.4bn clinical trials provider
Cinven has acquired clinical trials services provider Bioclinica from US private equity firms Water Street Healthcare Partners and JLL Partners.
- Water Street, JLL to sell Bioclinica to Cinven
Water Street Healthcare Partners and JLL Partners agreed to sell Doylestown, Pa.-based Bioclinica, Inc. to Cinven. Bioclinica provides outsourced clinical trial services. JLL Partners and Water Street merged Bioclinica and CCBR-SYNARC in 2014. The deal is expected to close in the fourth quarter.